Pharmaceutical aerosol formualtions containing fluorinated surfactants.

A pharmaceutical aerosol formulation which comprises particuiate medicament, a fluorocarbon or hydrogen-containing chlorofiuorocarbon propellant and a surfactant of general formula (I) O CnF2n+1(CH2)m-C-0-CH2 0 CnF2n+1(CH2)m-C-0-CH O il © R CH,-0-P-0-CH,CH,N-R 0 R wherein n is an integer of 1 to 18; m is an integer of 0 to 17; and R1, R2 and R3 are each independently a hydrogen atom or a Chalky! group.

Metered dose inhaler for beclomethasone dipropionate.

A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fiuorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

RATINGS WHERE THE PARTICLES ARE MADE BY PRECIPITING IN AN AEROSOL VESSEL

Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister

The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution; and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.

Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith

Pharmaceutical compositions that include an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith

Pharmaceutical compositions that include insulin, an insulin drug-oligomer conjugate, a fatty acid component, and a bile salt component or a bile salt component without a fatty acid component are described. The insulin drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1. Methods of treating an insulin deficiency in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister

The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution; and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.

Inhaler, inhaling system and the use thereof

A metered dose inhaler comprises a canister a crimped cap covering the mouth of the canister and a drug metering valve situated in the cap, for dispensing an inhalation drug formulation comprising salmeterol, or a physiologically acceptable salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients, said metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers and wherein the canister is a strengthened canister having a reduced tendency to malform under high temperatures, comprising side walls and base of increased thickness.

Metered dose inhaler for albuterol

Stable S-nitrosothiol formulations

Fluticazone propionate inhaler with dosis metering feature

MEDICINES.

FORMULACION FARMACEUTICA EN AEROSOL QUE INCLUYE MEDICAMENTO PARTICULADO, UN FLUOROCARBONO DE UN PROPELENTE DE CLOROFLUOROCARBONO QUE CONTIENE HIDROGENO Y UN SURFACTANTE DE LA FORMULA GENERAL (I), DONDE N ES UN INTEGRO DE 1 A 18; M ES UN INTEGRO DE 0 A 17; Y R{SUP,1}, R{SUP,2}, Y R{SUP,3} SON CADA UNO DE FORMA INDEPENDIENTE UN ATOMO DE HIDROGENO O UN GRUPO C{SUB,1-4} ALQUIL. PHARMACEUTICAL FORMULATION IN AEROSOL INCLUDING PARTICULATE MEDICINAL PRODUCT, A FLUOROCARBON OF A HYDROGEN-CONTAINING PROPELLENT OF HYDROGEN AND A SURFACTANT OF THE GENERAL FORMULA (I), WHERE N IS AN INTEGRATED 1 TO 18; M IS AN INTEGRO FROM 0 TO 17; AND R {SUP, 1}, R {SUP, 2}, AND R {SUP, 3} ARE EACH ONE INDEPENDENTLY A HYDROGEN ATOM OR A GROUP C {SUB, 1-4} ALKYL.

Medicaments

This invention relates to aerosol formulations of use for the administration of medicaments by inhalation. More particularly, the invention relates to a pharmaceutical aerosol formulation which comprises particulate salbutamol sulphate having a crystalline form in which the outer layer of the crystals is substantially non-amorphous; and 1,1,1,2-tetrafluoroethane. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.

Inhalator, inhaling system and the use thereof

A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

Metered dose inhaler for salmeterol

A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising salmeterol, or a physiologically acceptable salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

Dosage fixing inhaler for fluticazon propionate

The dosage fixing inhaler has partial or fully covered internal surfaces coated by one or more fluorocarbon polymers, optionally in combination with one or more nonfluorocarbon polymers. It is applied for the dispersion of medicamentous forms for inhalations consisting of fluticazon propionate or its physiologically acceptable solution and optionallyin fluorcarbon propellent combination with one or more pharmacologically active agents and one or more additional substances. 22 claims

Metered dose inhaler for fluticasone propionate

A metered dose inhaler has part or all of its internal surfaces coated with fluorinated ethylene propylene (FEP) and contains an inhalation drug formulation comprising fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

Preparation of suspension aerosol formulations

The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution; and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.

DOSAGE INHALATOR FOR FLUTICASONE PROPIONATE

Medicaments

Metered dose inhaler for fluticasone propionate

A metered dose inhaler has part or all of its internal surfaces coated with fluorinated ethylene propylene (FEP) and contains an inhalation drug formulation comprising fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

Stable S-nitrosothiol formulations

The invention provides stable S-nitrosothiol, such as S-nitrosoglutathione, formulations for long term storage and in vivo delivery of S-nitrosothiols. The invention provides stable aerosol formulations comprising S-nitrosothiol, such as S-nitrosoglutathione, and methods of treating patients in need of S-nitrosothiol, such as S-nitrosoglutathione, and/or nitric oxide treatment.

Metered dose inhaler for albuterol

A process for preparation of a metered dose inhaler suitable for containing a drug formulation having reduced susceptibility to drug adhesion to the inner surfaces which process comprises: i) providing a strengthened aluminium or aluminium alloy metered dose inhaler can capable of withstanding stressful coating and curing conditions; ii) providing a formulation of a coating polymer comprising one or more fluorocarbon polymers optionally in combination with one or more non-fluorocarbon polymers; iii) coating said can on its inside with said formulation of coating polymer; and iv) curing the coating on the can.

Metered dose inhaler for fluticasone propionate.

Metered dose inhaler for albuterol

Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith

Pharmaceutical compositions that include a drug and/or drug-oligomer conjugate, a fatty acid component and a bile salt component, or a bile salt component without a fatty acid component are described. The drug can be covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component, when together, can be present in a weight-to-weight ratio of between 1:15 and 15:1 or any value between. Methods of treating diseases in a subject in need of such treatment using the pharmaceutical compositions of this invention are also provided, as well as methods of providing such pharmaceutical compositions.

Metered dose inhaler for albuterol.

Metered dose inhaler metered dose inhaler system and use

Stable s-nitrosothiol formulations

The invention provides stable S-nitrosothiol, such as S-nitrosoglutathione, formulations for long term storage and in vivo delivery of S-nitrosothiols. The invention provides stable aerosol formulations comprising S-nitrosothiol, such as S-nitrosoglutathione, and methods of treating patients in need of S-nitrosothiol, such as S-nitrosoglutathione, and/or nitric oxide treatment.

Dose-measuring inhaler for fluticasone propionate

Metered dose inhaler for beclomethasone dipropionate

A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising beclomethasone dipropionate or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

Medicaments

A pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon of hydrogen-containing chlorofluoro-carbon propellant and a surfactant of general formula (I), wherein n is an integer of 1 to 18; m is an integer of 0 to 17; and R1, R2 and R3 are each independently a hydrogen atom or a C1-4alkyl group.

BECLOMETASONE DIPROPIONATE DOSING INHALER.

SE DESCRIBE UN INHALADOR DE DOSIS MEDIDA QUE POSEE TODAS O PARTE DE SU SUPERFICIE INTERNA RECUBIERTA CON UNO O MAS POLIMEROS DE FLUOROCARBONO, OPCIONALMENTE EN COMBINACION CON UNO O MAS POLIMEROS NO FLUOROCARBONADOS, PARA DISPENSAR UNA FORMULACION DE FARMACO INHALABLE QUE COMPRENDE DIPROPIONATO DE BECLOMETASONA O UN SOLVATO FISIOLOGICAMENTE ACEPTABLE DEL MISMO, Y UN PROPELENTE DE FLUOROCARBONO, OPCIONALMENTE EN COMBINACION CON UNO O MAS AGENTES FARMACOLOGICAMENTE ACTIVOS O UNO O MAS EXCIPIENTES. A DOSE INHALER IS DESCRIBED WHICH HAS ALL OR PART OF ITS INTERNAL SURFACE COVERED WITH ONE OR MORE FLUOROCARBON POLYMERS, OPTIONALLY IN COMBINATION WITH ONE OR MORE FLUOROCARBONATED POLYMERS, TO DISPENSE A FARMACOPE COMPLETE COMPLETE FORMULATION SOLVATO PHYSIOLOGICALLY ACCEPTABLE OF THE SAME, AND A FLUOROCARBON PROPELLENT, OPTIONALLY IN COMBINATION WITH ONE OR MORE PHARMACOLOGICALLY ACTIVE AGENTS OR ONE OR MORE EXCIPIENTS.

Metered dose inhaler for salmeterol

A metered dose inhaler comprises a canister a crimped cap covering the mouth of the canister and a drug metering valve situated in the cap, for dispensing an inhalation drug formulation comprising salmeterol, or a physiologically acceptable salt thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients, said metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers and wherein the canister is a strengthened canister having a reduced tendency to malform under high temperatures, comprising side walls and base of increased thickness.

Pharmaceutical compositions of drug-oligomer conjugates and methods of treating diseases therewith

Pharmaceutical compositions that include a drug-oligomer conjugate, a fatty acid component, and a bile salt component are described. The drug is covalently coupled to an oligomeric moiety. The fatty acid component and the bile salt component are present in a weight-to-weight ratio of between 1:5 and 5:1. Methods of treating diseases in a subject in need of such treatment using such pharmaceutical compositions are also provided, as are methods of providing such pharmaceutical compositions.

Process for manufacturing a metered dose inhaler

A metered dose inhaler having all or part of its internal surfaces coated with one or more fluorocarbon polymers, optimally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formation comprising albuterol or a physiologically acceptable salt thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

Medicaments

A pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon of hydrogen-containing chlorofluoro-carbon propellant and a surfactant of general formula (I), wherein n is an integer of 1 to 18; m is an integer of 0 to 17; and R1, R2 and R3 are each independently a hydrogen atom or a C1-4alkyl group.

Verfahren zur herstellung eines dosierinhalators

Vorrichtung zur dosierten inhalierung von beclomethason-diproprionat

Dosierinhalator für fluticasonepropionat

Dosierinhalator für fluticasonepropionat

Verfahren zur herstellung von suspensionsaerosolformulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden

Compuestos farmaceuticos de conjugados de farmaco de insulina-oligomero

SE REFIERE A COMPUESTOS QUE INCLUYEN A: a)UN CONJUGADO DE INSULINA OLIGOMERO UNIDOS COVALENTEMENTE A TRAVES DE LISINA EN LA POSICION B29 DE INSULINA DE FORMULA i)FARMACO DE INSULINA-B-Lj-Gk-R-G'm-R'-G"n-T; B ES UN GRUPO DE ENLACE, G, G', G" SON GRUPOS ESPACIADORES; R ES UN GRUPO LIPOFILICO; R' ES GLICOL POLIALQUILENO; T ES UN GRUPO TERMINAL; j, k, m Y n SON 0-1; ii) FARMACO DE INSULINA-X(CH2)mY(C2H4O)nR; X, Y SON ESTER, TIOESTER, ETER, CARBAMATO, TIOCARBAMATO, CARBONATO, TIOCARBONATO, AMIDA, UREA, ENLACE COVALENTE; m ES 1-24; n ES 1-50; R ES ALQUILO, AZUCAR, COLESTEROL, ADAMANTANO, ALCOHOL, ACIDO GRASO; SIENDO UN POLIPEPTIDO DE INSULINA HUMANA; b)ENTRE 0,1% Y 15% (P/V) DE ACIDO GRASO EN CANTIDAD SUFICIENTE PARA DISMINUIR EL PUNTO DE PRECIPITACION DE SAL BILIAR; c)ENTRE 0,1% A 15% (P/V) DE SAL BILIAR COMO ACIDO COLICO, PRESENTES EN UNA PROPORCION DE 1:5 Y 5:1, SIENDO pH DE 6,2 Y 9.0. LOS COMPUESTOS ESTAN PRESENTES COMO UNA MEZCLA MONODISPERSA; ADEMAS COMPRENDE UN AMORTIGUADOR COMO BASE TRIS Y TROLAMINA. LOS COMPUESTOS AL UTILIZAR SALES BILIARES Y ACIDOS GRASOS EN UN RATIO PARTICULAR PROPORCIONAN EFECTOS SINERGICOS INESPERADOS Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE INSUFICIENCIA DE INSULINA

Dosierinhalator für albuterol

Arzneimittel

Preparation of suspension aerosol formulations

The present invention provides processes for preparing suspension aerosol formulations, wherein the particles for inhalation are formed in situ during the process of manufacturing the formulation. In one aspect of the invention, a process for preparing a suspension aerosol formulation comprises the steps of: (a) dissolving one or more medicaments in one or more solvents to form a solution; and (b) mixing one or more propellants with the solution under conditions effective to precipitate, entirely or partially, at least one of the medicaments.